A Study to Compare Two Anti-HIV Drug Combinations

June 23, 2005 updated by: Hoffmann-La Roche

An Open Label, Randomized, Multicenter Study to Evaluate Fortovase (Saquinavir) SGC QD, Norvir (Ritonavir) QD Plus Two NRTIs Vs Sustiva (Efavirenz) QD Plus Two NRTIs in HIV Infected Patients

The purpose of this study is to compare 2 anti-HIV drug combinations.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients are stratified by HIV RNA: 5,000-75,000 vs greater than 75,000 copies/ml by Amplicor assay. Patients are randomized to two arms. Arm A receives SQV plus RTV plus two NRTIs. Arm B receives EFV plus two NRTIs. Patients must take their dose at approximately the same time every day. Patients have the option of taking daily dose in AM or PM. Patients are evaluated for changes in plasma HIV RNA levels and CD4/CD8 counts and for adverse experiences and laboratory determinations. Evaluations are made every 4-8 weeks until Week 48. Patients continuing beyond Week 48 who reach Weeks 60, 72, 84, and common study closure, will be seen at those weeks.

Study Type

Interventional

Enrollment

146

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada
        • Saint Paul's Hosp
    • Ontario
      • Toronto, Ontario, Canada
        • Toronto Gen Hosp
    • Quebec
      • Montreal, Quebec, Canada
        • Centre Hospitalier de la Universite de Montreal (CHUM)
  • Puerto Rico
      • Ponce, Puerto Rico, 00731
        • Ponce Univ Hosp
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Univ of Alabama at Birmingham / AIDS Outpatient Clinic
    • California
      • Long Beach, California, United States, 90813
        • St Mary's Med Ctr
      • San Francisco, California, United States, 94110
        • UCSF - San Francisco Gen Hosp
      • San Francisco, California, United States, 94118
        • Kaiser Foundation Hospital
    • District of Columbia
      • Washington, District of Columbia, United States, 20007
        • Georgetown Univ Med Ctr
      • Washington, District of Columbia, United States, 20037
        • Physicans Home Service
    • Florida
      • Fort Myers, Florida, United States, 33901
        • Associates in Research
      • Miami, Florida, United States, 33136
        • Univ of Miami / Jackson Memorial Hosp
    • Illinois
      • Chicago, Illinois, United States, 606575147
        • Illinois Masonic Med Ctr
    • New Jersey
      • Newark, New Jersey, United States, 07102
        • Saint Michael's Med Ctr / Dept of Infectious Diseases
      • Union, New Jersey, United States, 07083
        • Infectious Disease Specialists of NJ
    • New York
      • Elmhurst, New York, United States, 11373
        • Elmhurst Hosp
      • Jamaica, New York, United States, 11432
        • Queens Hospital Center
      • New Hyde Park, New York, United States, 11040
        • LIJMC
    • North Carolina
      • Greenville, North Carolina, United States, 27858
        • East Carolina Univ School of Medicine
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18105
        • Lehigh Valley Hosp
    • South Carolina
      • Columbia, South Carolina, United States, 29206
        • Burnside Clinic
      • Greenville, South Carolina, United States, 29605
        • Greenville Hospital System
    • Texas
      • Dallas, Texas, United States, 75246
        • Nicholas Bellos
      • Houston, Texas, United States, 77004
        • Joseph Gathe
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • Univ of Utah
    • Washington
      • Seattle, Washington, United States, 98104
        • Univ of Washington / AIDS Clinical Trial Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have a viral load of at least 5,000 copies/ml and a CD4 cell count of at least 75 cells/mm3.
  • Are at least 18.
  • Are able to complete the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have taken any anti-HIV medications for more than 2 weeks.
  • Are pregnant or breast-feeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hoffmann-La Roche

Investigators

  • Principal Investigator: JSG Montaner
  • Study Chair: Danielle Rouleau
  • Study Chair: Michael Saag
  • Study Chair: Paul Volberding
  • Study Chair: Sharon Walmsley
  • Study Chair: Nicholas Bellos
  • Study Chair: Alfred Burnside
  • Study Chair: Stephen Follansbee
  • Study Chair: Joseph Gathe
  • Study Chair: Bruce Hathaway
  • Study Chair: Margaret Hoffman-Terry
  • Study Chair: Jazila Mantis
  • Study Chair: Joseph Masci
  • Study Chair: Mahmoud Mustafa
  • Study Chair: John Schrank
  • Study Chair: Malte Schutz
  • Study Chair: Leon Smith

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 1999

Study Registration Dates

First Submitted

November 2, 1999

First Submitted That Met QC Criteria

August 30, 2001

First Posted (Estimate)

August 31, 2001

Study Record Updates

Last Update Posted (Estimate)

June 24, 2005

Last Update Submitted That Met QC Criteria

June 23, 2005

Last Verified

January 1, 2001

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 229R
  • NR15720C/M61027

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on Ritonavir

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe